Literature DB >> 11581147

Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes.

K Yamamoto1, R Ohki, R T Lee, U Ikeda, K Shimada.   

Abstract

BACKGROUND: Peroxisome proliferator-activated receptors (PPARs) are transcription factors belonging to the nuclear receptor superfamily. PPARgamma mRNA is present in cardiac myocytes; however, whether PPARgamma affects cardiac hypertrophy remains unknown. METHODS AND
RESULTS: We investigated the effects of PPARgamma activators on cardiac hypertrophy in neonatal rat cardiac myocytes. Cyclic 4% biaxial mechanical strain caused enlargement of cardiac myocytes (1.3-fold versus control, P<0.0001), but the PPARgamma activators troglitazone and 15-deoxy-Delta(12-14)-prostaglandin J(2) (15d-PGJ(2)) (10 micromol/L) inhibited this effect (troglitazone, -72%, P<0.0005; 15d-PGJ(2), -88%, P<0.0002). Total cell protein was increased by mechanical strain (control, 164.3 microgram/dish; strain, 265.5, P<0.0002), and this effect was inhibited by troglitazone and 15d-PGJ(2) (troglitazone, -61%, P<0.005; 15d-PGJ(2), -72%, P<0.001). [(3)H]Leucine uptake was also increased by mechanical strain (1.9-fold versus control, P<0.002), and this increase was inhibited by troglitazone and 15d-PGJ(2) (troglitazone, -52% at 10 micromol/L, P<0.01; 15d-PGJ(2), -70% at 10 micromol/L, P<0.005). An increase in [(3)H]leucine uptake induced by angiotensin II or phenylephrine was significantly inhibited by troglitazone and 15d-PGJ(2). Mechanical strain induced mRNA expression for brain natriuretic peptide, but PPARgamma activators inhibited this induction. Furthermore, PPARgamma activators inhibited mechanically induced activation of nuclear factor (NF)-kappaB. Pyrrolidine dithiocarbamate, an inhibitor of NF-kappaB activation, inhibited strain-induced [(3)H]leucine uptake (-50% at 100 micromol/L, P<0.05).
CONCLUSIONS: These results demonstrate that PPARgamma activators inhibit cardiac hypertrophy in cardiac myocytes and suggest that PPARgamma activators may regulate cardiomyocyte hypertrophy at least partially through the NF-kappaB pathway.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11581147     DOI: 10.1161/hc4001.097186

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  51 in total

Review 1.  Peroxisome proliferator-activated receptors: lipid binding proteins controling gene expression.

Authors:  Marc van Bilsen; Ger J van der Vusse; Andries J Gilde; Martijn Lindhout; Karin A J M van der Lee
Journal:  Mol Cell Biochem       Date:  2002-10       Impact factor: 3.396

2.  Endogenously produced adiponectin protects cardiomyocytes from hypertrophy by a PPARgamma-dependent autocrine mechanism.

Authors:  Rajesh H Amin; Suresh T Mathews; Adebisi Alli; Todd Leff
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-07-09       Impact factor: 4.733

3.  NADPH oxidase 4 induces cardiac fibrosis and hypertrophy through activating Akt/mTOR and NFκB signaling pathways.

Authors:  Qingwei David Zhao; Suryavathi Viswanadhapalli; Paul Williams; Qian Shi; Chunyan Tan; Xiaolan Yi; Basant Bhandari; Hanna E Abboud
Journal:  Circulation       Date:  2015-01-14       Impact factor: 29.690

4.  Serum MicroRNA-27b as a Screening Biomarker for Left Ventricular Hypertrophy.

Authors:  Yan Wang; Shuyan Chen; Yanhong Gao; Song Zhang
Journal:  Tex Heart Inst J       Date:  2017-12-19

5.  Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes.

Authors:  Beate Fiedler; Suzanne M Lohmann; Albert Smolenski; Stephan Linnemuller; Burkert Pieske; Frank Schroder; Jeffery D Molkentin; Helmut Drexler; Kai C Wollert
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

6.  Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction.

Authors:  Stefan Frantz; Kai Hu; Julian Widder; Barbara Bayer; Catharina Clara Witzel; Isabel Schmidt; Paolo Galuppo; Jörg Strotmann; Georg Ertl; Johann Bauersachs
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

7.  Ligands of the peroxisome proliferator-activated receptor-gamma and heart failure.

Authors:  C Thiemermann
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

8.  Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol.

Authors:  Paras K Mishra; Neetu Tyagi; Utpal Sen; Irving G Joshua; Suresh C Tyagi
Journal:  Cardiovasc Diabetol       Date:  2010-09-09       Impact factor: 9.951

9.  Simvastatin activates the PPARγ-dependent pathway to prevent left ventricular hypertrophy associated with inhibition of RhoA signaling.

Authors:  Cao Zou; Hongtao Qi; Zhi-hua Liu; Lianhua Han; Caiming Zhao; Xiangjun Yang
Journal:  Tex Heart Inst J       Date:  2013

10.  Defective peroxisomal proliferators activated receptor gamma activity due to dominant-negative mutation synergizes with hypertension to accelerate cardiac fibrosis in mice.

Authors:  Adrienn Kis; Colin Murdoch; Min Zhang; Anjana Siva; Sergio Rodriguez-Cuenca; Stefania Carobbio; Agnes Lukasik; Margaret Blount; Steve O'Rahilly; Sarah L Gray; Ajay M Shah; Antonio Vidal-Puig
Journal:  Eur J Heart Fail       Date:  2009-04-24       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.